Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2024 16:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader program Members of the Nurix management...
October 19, 2024 08:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial Responses are durable and...
October 16, 2024 16:35 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
October 11, 2024 16:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom’s...
October 09, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
September 30, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
September 06, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
August 29, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
July 11, 2024 16:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with...
July 08, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day

SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...